Spiriva Promotion Should Mention Atrovent HFA Availability, DDMAC Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s ad division calls a Boehringer Ingelheim promotion highlighting the discontinuation of Atrovent MDI misleading.